Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational follow-up of immune response duration after Cervarix vs Gardasil in UK adolescent females
2016-002083-13Phase 4Completed
- Sponsor
- UK Health Security Agency
- Start
- Jul 2016
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in human papillomavirus infection, Cervical Cancer (CC) and Ano-genital Carcinoma comparing Gardasil recipients with Cervarix recipients (2 arms). Primary endpoints: Duration of immune response to HPV vaccine types and Immune response to non-vaccine HPV types. Started Jul 2016; status: completed.
02
Drugs
qHPV vaccinehuman papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infectionCervical Cancer (CC)Ano-genital Carcinoma
Beyond the preview
Go deeper on 2016-002083-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002083-13.